

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number
WO 01/72746 A1

(51) International Patent Classification⁷: C07D 457/06,
A61K 31/47, A61P 25/00

Della Guerrina, 33, I-20052 Monza (IT). UNGARI,
Mario [IT/TT]; Via Pietro Calvi, 10, I-20129 Milan (IT).

(21) International Application Number: PCT/EP01/02969

(22) International Filing Date: 15 March 2001 (15.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0007309.8 24 March 2000 (24.03.2000) GB

(71) Applicant (for all designated States except US): PHAR-
MACIA & UPJOHN SPA [IT/TT]; Via Robert Koch, 1.2,
I-20152 Milan (IT).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): CANDIANI, Ilaria
[IT/IT]; Via Marengo, 13, I-21052 Busto Arsizio (IT).
BUDELLI, Raffaella [IT/TT]; Via Bellavista, 29, I-21018
Sesto Calende (IT). PANDOLFI, Marco [IT/IT]; Via

(54) Title: CRYSTALLINE FORM VII OF CABERGOLINE



(57) Abstract: Crystalline form VII of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise a slurry procedure using form I or mixture of forms I and VII of cabergoline in a solvent at a temperature above 30 °C.

WO 01/72746 A1

Crystalline form VII of cabergoline

The present invention concerns a new crystalline form of cabergoline, a pharmaceutical composition thereof and its use as therapeutically active agent, alone or in
5 combination. Another aspect of the present invention relates to the preparation of this crystalline form. Cabergoline is an ergoline derivative interacting with D2 dopamine receptors and is endowed with different useful pharmaceutical activities and it is used in the treatment
10 of hyperprolactinemia, central nervous system disorders (CNS) and other related diseases.

Cabergoline is the generic name of 1((6-allyl-ergolin-8 β -yl)-carbonyl)-1-(3-dimethylaminopropyl)-3-ethylurea, described and claimed in US 4,526,892. The synthesis of
15 Cabergoline molecule is reported also in European. J. Med. Chem., 24,421, (1989) and in GB-2,103,603-B.

During our work we discovered that cabergoline can exist in at least two crystalline forms under ambient conditions. One form (coded Form I) is an anhydrous not solvated form
20 and, to our knowledge, it is the only form reported in the literature to date. Form VII is an anhydrous not solvated form too.

Thus, the present invention concerns a new polymorph (Form VII) of cabergoline and the preparation thereof. Another
25 aspect relates to samples of cabergoline Form VII having a % polymorphic purity >90%, preferably >99%. The invention further provides a pharmaceutical composition of cabergoline Form VII and its use as therapeutic agent.

Description of figures

- 30 Figure 1. XRD powder pattern of cabergoline Form VII.
Figure 2. DSC curve of cabergoline Form VII.
Figure 3. IR spectrum of cabergoline Form VII (sample prepared by KBr powder technique).
Figure 4. Solid state ^{13}C -NMR spectrum of cabergoline form
35 VII.

Form VII is the thermodynamically most stable polymorph in a range of temperature between +30° and +80°C. It can be readily prepared by slurry of form I or mixture of form I and VII in a solvent at a temperature over 30°C. The
40 importance of cabergoline form VII rests primarily (but not

exclusively) in thermodynamic stability.

Form VII shows advantages with respect to form I because of its greater stability.

Characterisation

- 5 X-ray powder diffraction (XRD), differential scanning calorimetry (DSC), infrared (IR) spectroscopy and solid state ^{13}C -NMR were used to characterise the new form.

X-Ray Powder Diffraction

- Powder X-ray diffraction was performed using either a
10 Scintag X1 or X2 Advanced Diffraction System operating under Scintag DMS/NT[®] Ver 1.30a and 1.36b respectively, and Microsoft Windows NT 4.0[™] software. The system used a copper X-ray source maintained at 45 kV and 40 mA to provide $\text{CuK}\alpha_1$ emission of 1.5406 angstroms and a solid
15 state peltier cooled detector. Beam aperture was controlled using tube divergence and anti-scatter slits of 2 and 4 mm and detector anti-scatter and receiving slits of 0.5 and 0.3 mm width. Data were collected from 2 to 40° two-theta using a step scan of 0.03°/point with a one second/point
20 counting time. The samples were hand ground using a pestle and mortar and packed into an aluminum sample tray with a 12 mm (diam.) x 0.5 mm cavity.

DSC

- Measurements of differential scanning calorimetry were
25 obtained on a Mettler TA 4000 thermal analysis system. Approximately 8.5 mg samples were accurately weighed into a DSC Pan. The pans were hermetically sealed and a pinhole was punched into the Pan lid. The use of the pinhole allows for pressure release, but still assures that the thermal
30 reactions proceed under controlled conditions. The samples were introduced into the DSC oven and then heated at a rate of 5°C/min, up to a final temperature of 135°C.

IR Spectroscopy

- IR spectrum of cabergoline form VII was obtained on a
35 Perkin Elmer FT-IR spectrophotometer PARAGON 1000. The sample was prepared by KBr powder technique registering the spectrum on reflectance.

Solid state ^{13}C -NMR

- Solid state ^{13}C -NMR spectra were obtained on a MSL 300
40 Bruker instrument equipped with solid state facilities and

variable temperature magic angle spinning probe. Cross polarisation experiments were performed by a decoupling field of 50 KHz and single pulse magic angle spinning experiments with recycle times ranging from 10 to 100 records.

The XRD, DSC, IR and NMR curves are shown in Figures 1-4 respectively.

The x-ray powder diffraction pattern for Form VII (Figure 1) shows a crystalline structure with useful distinctive peaks at approximately 5.6, 8.1, 10.6 and 10.8 ° 2-theta. The DSC curve of Form VII (Figure 2) exhibits a melting endotherm at approximately 121°C. The integrated melting endotherm has a heat of fusion of approximately 60 J/g. The IR spectrum of Form VII is shown in Figure 3. The solid state ¹³C-NMR spectrum of form VII is shown in figure 4.

These data indicate that cabergoline Form VII is a crystalline polymorph easily distinguishable from form I by XRD, DSC and solid state ¹³C-NMR techniques. IR, combined with another analytical technique, is another method to distinguish the two polymorphs. The difference is a band in the region of 3500 cm⁻¹ that appears like a shoulder of a greater signal.

Crystalline cabergoline I has been reported in Il Farmaco, 50 (3), 175-178 (1995). However, to applicants' knowledge, no one has reported any other crystalline form.

In summary, cabergoline exists in at least two crystalline forms. Form I is a crystal (melting point = 98°-105°C by DSC, heat of fusion of ~60 J/g) with a characteristic powder XRD pattern and ¹³C-NMR spectrum.

Form VII is a crystalline (melting point = 121°C by DSC, heat of fusion about 60 J/g) with characteristic powder XRD pattern and ¹³C-NMR spectrum. DSC too is very different from that of form I.

The present invention also provides a process for producing crystalline cabergoline Form VII by subjecting crystals of form I or a mixture of crystals form I and VII to a slurry procedure at a temperature over 30°C. Preferably, the process comprises suspending crystals of form I or a mixture of crystals form I and VII in an organic solvent,

such as n-heptane, diethyl ether, or n-hexane, at a temperature of from +30° to +80°C, more preferably about 55°C. The resultant suspension is then stirred at this temperature for about from 24 to 120 hours, more preferably
5 for about 48 hours.

The thus obtained crystals of Form VII may be recovered by common procedures, for example by filtration under reduced pressure or by centrifugal filtration, followed by drying the crystals, to obtain the crystalline Form VII
10 cabergoline of the present invention. Like cabergoline Form I, Form VII displays a significant inhibitory effect with regard prolactin and has therapeutic properties that make it possible to treat patients who have pathological conditions associated with an abnormal prolactin level,
15 thus is useful in human and/or veterinary medicine. Cabergoline is also active, alone or in combination, in the treatment of reversible obstructive airways diseases, for controlling intraocular pressure and for the treatment of glaucoma. It is also employed in the veterinary field, as
20 antiprolactin agent and in cutting down drastically the proliferation of vertebrate animals. The several uses of cabergoline are for example described in WO9948484, WO9936095, US5705510, WO9505176, EP040325.

Forms VII in accordance with the invention is particularly
25 useful in the treatment of Parkinson's disease (PD), Restless Legs Syndrome (RLS), treatment of diseases like Progressive Supranuclear Palsy (PSP) and Multisystemic atrophy (MSA). Thus, another aspect of the instant invention concerns a method for treatment of Parkinson's
30 disease (PD), Restless Legs Syndrome (RLS), Progressive Supranuclear Palsy (PSP) and Multisystemic atrophy (MSA) which comprises administering to a host an effective amount of cabergoline Form VII .

Cabergoline Forms VII of the present invention may be used
35 in a manner similar to that of cabergoline Form I; therefore, a person skilled in the art of CNS diseases treatment will be able to ascertain, without undue experimentation, an appropriate treatment protocol for administering a compound of the present invention. The
40 dosage, mode and schedule of administration for compounds

of this invention are not particularly restricted, and will vary with the particular compound employed. Thus Forms VII of the present invention may be administered via any suitable route of administration, preferably orally. For
5 CNS diseases treatment, the dosage may be, for example, in the range of about 0.5 to about 50 mg/patient/day, preferably 2 to 4 mg daily as monotherapy and 2 to 6 mg daily as adjuvant therapy. The actual dose used will vary according to the particular composition formulated, the
10 route of administration, and the particular disease being treated. Many factors that modify the action of the drug will be taken into account in determining the dosage including age, weight, sex, diet and the physical condition of the patient.

15 The present invention also provides pharmaceutical compositions (formulations) containing an effective amount of Form VII in combination with one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants.

20 For example, Form VII invention may be formulated in the form of tablets, pills, powder mixtures, capsules, injectables, solutions, suspensions, suppositories, emulsions, dispersions, food premix, and in other suitable forms. It may also be manufactured in the form of sterile
25 solid compositions, for example, freeze dried and, if desired, combined with other pharmaceutically acceptable excipients. Such solid compositions can be reconstituted with sterile water, physiological saline, or a mixture of water and an organic solvent, such as propylene glycol,
30 ethanol, and the like, or some other sterile injectable medium immediately before use for parenteral administration as a suspension (microdispersion) or in solution. Typical of pharmaceutically acceptable carriers are, for example, manitol, urea, dextrans, lactose, potato and maize
35 starches, magnesium stearate, talc, vegetable oils, polyalkylene glycols, ethyl cellulose, poly(vinylpyrrolidone), calcium carbonate, ethyl oleate, isopropyl myristate, benzyl benzoate, sodium carbonate, gelatin, potassium carbonate, silicic acid. The
40 pharmaceutical preparation may also contain nontoxic

- auxiliary substances such as emulsifying, preserving, wetting agents, and the like as for example, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene monostearate, glyceryl tripalmitate, dioctyl sodium
- 5 sulfosuccinate, and the like.

Example 1.

- 55.5 g of crystalline cabergoline form I were added to 700 ml of n-heptane at 55°C. The suspension was stirred at this temperature for about 48 hours and then filtered using a
- 10 glass filter under vacuum. The resulting crystals were dried under vacuum at 40°C for 24 hours. After drying the resultant crystal form VII was identified by XRD, DSC, IR and NMR, data shown in figures 1-4 respectively, having polymorphic purity >99%.

15 Example 2.

- 27.65g of cabergoline were dissolved in 1,4-dioxane at 40°C; the final solution (68 mL) was slowly cooled till to -5°C, in stirring. After 24 hours the obtained solid was filtered on sintered-glass G4 filter and then dried at from
- 20 30°C to 65°C under N₂ and vacuum. The resultant crystals form VII were identified by DSC and IR. Yield was 45.2%.

CLAIMS

1. Crystalline form VII of cabergoline.
2. Crystalline form VII of cabergoline according to claim 1
5 which is anhydrous, non-solvated and has a percentage
purity greater than 92%.
3. Crystalline form VII of cabergoline according to claim 1
which is anhydrous, non-solvated and has a percentage
purity greater than 99%.
- 10 4. Crystalline form VII of cabergoline having the XRD
powder pattern of Figure 1.
5. A pharmaceutical composition which comprises an
effective amount of crystalline Form VII, as defined in any
one of claims 1 to 4 in combination with one or more
15 pharmaceutically acceptable carriers, excipients, diluents
or adjuvants.
6. A process for producing cabergoline Form VII as defined
in any one of claims 1 to 4, which process comprises
subjecting crystals of form I, or a mixture of forms I and
20 VII, of cabergoline to a slurry procedure at a temperature
above 30°C, followed by recovery and drying of the
resulting crystals.
7. A process according to claim 6 in which the slurry
procedure comprises suspending crystals of form I or a
25 mixture of forms I and VII of cabergoline in an organic
solvent, at a temperature of from +30° to +80°C, and
stirring the resultant suspension for from 24 to 120 hours.
8. A process according to claim 7 in which the solvent is
diethyl ether, n-heptane or n-hexane.

FIG. 1




FIG. 2




FIG. 3





FIG. 4



INTERNATIONAL SEARCH REPORT

International Application No

PCT/E. 01/02969

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D457/06 A61K31/47 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHEMICAL ABSTRACTS, vol. 122, no. 21, 22 May 1995 (1995-05-22) Columbus, Ohio, US; abstract no. 265741, P. SABATINO ET AL.: "X-ray crystal structure and conformational analysis of N-(3-dimethylaminopropyl)-N-(ethylaminocar bonyl)-6-(2-propenyl)ergoline-8.beta.-carb oxamide (cabergoline): comparison with bromocriptine and lisuride and a hypothesis for its high dopaminergic activity" XP002170287 cited in the application abstract & FARMACO, vol. 50, no. 3, 1995, pages 175-178, --- -/--	1-7

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *B* document member of the same patent family

Date of the actual completion of the international search

21 June 2001

Date of mailing of the international search report

04/07/2001

Name and mailing address of the ISA

European Patent Office, P B 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel (+31-70) 340-2040, Tx 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Herz, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/E. 01/02969

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99 48484 A (PHARMACIA & UPJOHN COMPANY) 30 September 1999 (1999-09-30) claims 1-31 ---	1-7
Y	WO 99 59563 A (PHARMACIA & UPJOHN COMPANY) 25 November 1999 (1999-11-25) claims 1-24 ---	1-7
Y	GB 2 103 603 A (FARMITALIA CARLO ERBA SPA) 23 February 1983 (1983-02-23) cited in the application claims 1-3 ---	1-7
Y	US 4 526 892 A (P. SALVATI ET AL.) 2 July 1985 (1985-07-02) cited in the application claims 1-4 -----	1-7

INTERNATIONAL SEARCH REPORT

In relation on patent family members

International Application No

PCT/E. 01/02969

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9948484 A	30-09-1999	AU 3353199 A BR 9908953 A EP 1066038 A NO 20004799 A US 6114326 A	18-10-1999 05-12-2000 10-01-2001 11-10-2000 05-09-2000
WO 9959563 A	25-11-1999	AU 3741999 A BR 9909917 A EP 1076559 A NO 20005757 A	06-12-1999 26-12-2000 21-02-2001 14-11-2000
GB 2103603 A	23-02-1983	BE 894060 A DE 3229665 A JP 1655200 C JP 3021030 B JP 58038282 A	01-12-1982 24-02-1983 13-04-1992 20-03-1991 05-03-1983
US 4526892 A	02-07-1985	BG 61058 B	30-09-1996